Hikma Advances $250m Buyback, Shrinks Share Count Further

An announcement from Hikma Pharmaceuticals ( (GB:HIK) ) is now available.

Hikma Pharmaceuticals has continued executing its $250 million share buyback, repurchasing ordinary shares on the London Stock Exchange and Cboe Europe between 20 and 24 April 2026, with prices generally in the mid-1300 pence range. The company plans to cancel these shares, and since launching the programme in February it has acquired 4.88 million shares for £61.7 million, reducing free float and leaving 217,006,216 voting shares in issue, a move that signals confidence in its balance sheet and capital-return strategy for shareholders.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on HIK Stock

According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals group listed in London and on Nasdaq Dubai. The company focuses on manufacturing and supplying injectable medicines, branded generics and non-injectable generics to hospitals and healthcare systems in global markets, with a strong presence in the Middle East, North Africa, Europe and the U.S.

Average Trading Volume: 1,407,957

Technical Sentiment Signal: Sell

Current Market Cap: £2.99B

For a thorough assessment of HIK stock, go to TipRanks’ Stock Analysis page.